Several TLS cases after CD19 CAR-T therapy have been observed (4, 16); however, TLS in the context of BCMA-targeted CAR-T therapy has not been reported, and recognizing TLS as a vital CAR-T cell-related toxicity is imperative. Here, TNFRSF17 is linked to Tumor Lysis Syndrome.